Holen Sie sich die Stockscreener-App
5.20
13.76%
-0.83
Handel nachbörslich:
5.03
-0.17
-3.27%
Schlusskurs vom Vortag:
$6.03
Offen:
$4.75
24-Stunden-Volumen:
5.68M
Relative Volume:
4.22
Marktkapitalisierung:
$15.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.60M
KGV:
-5.8427
EPS:
-0.89
Netto-Cashflow:
$-23.48M
1W Leistung:
+21.21%
1M Leistung:
+27.14%
6M Leistung:
-60.02%
1J Leistung:
-84.52%
1-Tages-Spanne:
$4.60
$5.38
1-Wochen-Bereich:
$3.99
$9.82
52-Wochen-Spanne:
$3.09
$36.60
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Firmenname
Briacell Therapeutics Corp
Sektor
Branche
Telefon
(604) 921-1810
Adresse
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Vergleichen Sie BCTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
5.20 | 15.54M | 0 | -16.60M | -23.48M | -0.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-02-14 | Eingeleitet | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Aktie (BCTX) Neueste Nachrichten
(BCT) Trading Performance and Risk Management (BCT:CA) - news.stocktradersdaily.com
BriaCell (BCTX) Prices Public Offering of Units to Raise $13.8 M - GuruFocus
Increased Share Offering for XYZ Corp (XYZ) Priced Below Market - GuruFocus
BriaCell Stock Dips After-Hours On Pricing $13.8M Public Offering, But Retail's Busy Cheering Clinical Milestone - MSN
BriaCell Therapeutics (BCTX) Prices $13.8 Million Public Offerin - GuruFocus
BriaCell's Stock Dips Following Public Offering Announcement - Finimize
BriaCell Therapeutics Down 17% In US Premarket As Prices US$13.8 Million Public Offering - marketscreener.com
BriaCell Therapeutics announces pricing of $13.8 million public offering - MSN
(BCT) Trading Report (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering | BCTX Stock News - GuruFocus
BriaCell Stock Dips After-Hours On Pricing $13.8M Public Offering, But Retail’s Busy Cheering Clinical Milestone - Investing.com India
BriaCell Therapeutics Announces $13.8 Million Public Offering - TipRanks
BriaCell Raises $13.8M: Strong Institutional Demand Drives Full Exercise of Underwriter Option - Stock Titan
Briacell Therapeutics Says Units Priced At $4.50 Each For Gross Proceeds Of $13.8 Million - marketscreener.com
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering - GlobeNewswire
BriaCell reports complete lung metastasis resolution in breast cancer study By Investing.com - Investing.com South Africa
BriaCell's Bria-OTS shows sustained success against breast cancer | 2025-04-24 | Investing News - Stockhouse
BriaCell confirms 100% resolution of lung metastasis with Bria-OTS - TipRanks
Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher - Benzinga
BriaCell (BCTX) Showcases Key Breast Cancer Trial Data at ASCO 2025 - GuruFocus
BriaCell Jumps 41% in U.S. Pre-market Trading, Reports Complete Lung Metastasis Resolution in Patient - marketscreener.com
BriaCell (BCTX) Reports Positive Outcomes in Bria-OTS Cancer Study | BCTX Stock News - GuruFocus
BriaCell’s Bria-OTS Shows Promising Results in Metastatic Breast Cancer Study - TipRanks
BriaCell Therapeutics stock soars on lung metastasis treatment success By Investing.com - Investing.com Nigeria
BriaCell reports complete lung metastasis resolution in breast cancer study - Investing.com India
BriaCell Therapeutics stock soars on lung metastasis treatment success - Investing.com
BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™ | BCTX Stock News - GuruFocus
BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™ - GlobeNewswire
Breakthrough: BriaCell's Novel Cancer Treatment Eliminates Lung Metastasis in Advanced Breast Cancer Patient - Stock Titan
H.C. Wainwright maintains $32 target on BriaCell stock - Investing.com Australia
H.C. Wainwright maintains $32 target on BriaCell stock By Investing.com - Investing.com South Africa
BriaCell Therapeutics Corp. - Baystreet.ca
Stocks In Play: BriaCell Therapeutics Corp. - Barchart.com
BriaCell Announces Four Clinical Data Presentations at ASCO 2025 - GuruFocus
BriaCell to Present Key Clinical Data at ASCO 2025 - TipRanks
BriaCell Announces Four Clinical Data Presentations at ASCO 2025 | BCTX Stock News - GuruFocus
Major Phase III Breast Cancer Treatment Update: BriaCell Unveils 4 Clinical Studies at ASCO 2025 - Stock Titan
Briacell Therapeutics Files For Offering Of Up To 2.3 Mln Common Units, Up To 2.3 Mln Pre-Funded Units - marketscreener.com
Innovative Company Announces New Common Unit Offering | BCTX Stock News - GuruFocus
BriaCell Therapeutics: Promising Phase 3 Trial Progress and Strategic Financial Management Justify Buy Rating - TipRanks
BriaCell Enrollment Accelerates In Phase 3 Study For Advanced Metastatic Breast Cancer - Nasdaq
BriaCell Advances Phase 3 Study in Metastatic Breast Cancer - TipRanks
BriaCell (BCTX) Advances Phase 3 Trial for Bria-IMT in Metastatic Breast Cancer | BCTX Stock News - GuruFocus
BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC) - GlobeNewswire
Fast-Tracked Phase 3 Breast Cancer Treatment Shows Major Enrollment Surge: 75 Patients Join Critical Trial - Stock Titan
(BCT) Daily Stock Insights (BCT:CA) - news.stocktradersdaily.com
Finanzdaten der Briacell Therapeutics Corp-Aktie (BCTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):